Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: A pragmatic trial

PharmacoEconomics

Volumn 28, Issue 7, 2010, Pages 597-608

  Wilson, Edward C F ^a   Price, David ^a,b   Musgrave, Stanley D ^a   Sims, Erika J ^a   Shepstone, Lee ^a   Murdoch, Jamie ^a   Mugford, H Miranda ^a   Blyth, Annie ^a   Juniper, Elizabeth F ^c   Ayres, Jon G ^d   Wolfe, Stephanie ^e   Freeman, Daryl ^b,f   Gilbert, Richard F T ^g   Hillyer, Elizabeth V ^h   Harvey, Ian ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e Thorpewood Surgery   (United Kingdom)

^f Sheringham Medical Practice   (United Kingdom)

^g Castle Partnership   (United Kingdom)

^h Research in Real Life   (United Kingdom)

Author keywords

asthma, treatment; beta adrenergic receptor agonists, therapeutic use; corticosteroids, therapeutic use; cost effectiveness; cost utility; leukotriene D4 receptor antagonists, therapeutic use

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALMETEROL XINAFOATE; ZAFIRLUKAST;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI ASTHMA QUALITY OF LIFE QUESTIONNAIRE; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNITED KINGDOM;

EID: 77953714902     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11537560-000000000-00000     Document Type: Article

References (36)

1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478
2. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636-642
3. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002; 20: 260-267
4. Rabe KF, AdachiM, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47
5. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis: I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107: 3-8
6. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. London: NHS Quality Improvement Scotland, 2008 May, updated 2009 Jun [online]. Available from URL: http://www.sign.ac.uk/guidelines/ fulltext/101/index.html [Accessed 2010 Apr 23]
7. Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention [online]. Available from URL: http://www.ginasthma. org/GuidelinesResources. asp?l1=2&l2=0 [Accessed 2010 Apr 23]
8. Herland K, Akselsen JP, Skjonsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger 'real life' population of patients with obstructive lung disease? Respir Med 2005; 99: 11-19
9. Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219-223
10. Lemanske RF, Mauger DT, Sorkness C, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362 (11): 975-985
11. De Maeseneer JM, van Driel ML, Green LA, et al. The need for research in primary care. Lancet 2003; 362: 1314-1319
12. Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med 2006; 6 Suppl. 1: S6
13. Price D, Musgrave SD, Wilson E, et al. A pragmatic singleblind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines. Health Technol Assess. In press
14. British National Formulary. 50th ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2005
15. Department of Health. NHS reference costs 2004-2005: appendix 4 [online]. Available from URL: http://www.dh. gov.uk/prod-consum-dh/groups/dh- digitalassets/@dh/@ en/documents/digitalasset/dh-4133228.xls [Accessed 2010 Apr 23]
16. Office for National Statistics. Annual Survey of Hours and Earnings (ASHE). 2005 [online]. Available from URL: http://www.statistics.gov.uk/ StatBase/Product.asp?vlnk=1 3101 [Accessed 2010 Apr 23]
17. Office for National Statistics. All items retail prices index (RPI): table (RP02). London: Office for National Statistics [online]. Available from URL: http://www.statistics.gov. uk/statbase/product.asp?vlnk=9412 [Accessed 2010 Apr 23]
18. HM Treasury. The green book: appraisal and evaluation in central government. London: HM Treasure: section 5.49 [online]. Available from URL: http://www.hmtreasury. gov.uk/d/green-book-complete.pdf [Accessed 2010 Apr 23]
19. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2008 Jun: section 5.6 [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf [Accessed 2010 Apr 23]
20. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14: 32-38
21. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553-558
22. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
23. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72
24. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108
25. Drummond MF, Sculpher MJ, Torrance GW, et al. Quality adjusted life years. In: Drummond MF, Sculpher MJ, Torrance GW, et al., editors. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005: 173-188
26. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken (NJ): John Wiley & Sons, 1987
27. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-787
28. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2008 Jun: sections 6.2.21-6.2.25 [online]. Available from URL: http://www.nice.org.uk/media/B52/ A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2010 Apr 23]
29. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173: 379-385
30. Litonjua AA. The significance of beta2-adrenergic receptor polymorphisms in asthma. Curr Opin Pulm Med 2006; 12: 12-17
31. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-364
32. Briggs AH. New methods of analysing cost effectiveness. BMJ 2007; 335: 622-623
33. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109: 433-439
34. Pieters WR, Wilson KK, Smith HC, et al. Salmeterol/ fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treat Respir Med 2005; 4: 129-138
35. O'Connor RD, Nelson H, Borker R, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22 (12): 815-825
36. Storms W. Clinical trials: are these your patients? J Allergy Clin Immunol 2003; 112: S107-11